Mutation analysis of five candidate genes in familial breast cancer

Breast Cancer Research and Treatment

Volumn 105, Issue 3, 2007, Pages 377-389

  Marsh, Anna ^a   Healey, Sue ^a   Lewis, Aaron ^a   Spurdle, Amanda B ^a   Kedda, Mary Anne ^b   Khanna, Kum Kum ^a   Mann, Graham J ^c   Pupo, Gulietta M ^c   Lakhani, Sunil R ^a,d   Chenevix Trench, Georgia ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ATR; BRCA1 2; CHK1; EIF2S6 Int 6; Familial breast cancer; PPP2R1B; PPP2R5B

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; PHOSPHOPROTEIN PHOSPHATASE 2A;

ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST TUMOR; CHROMOSOMAL INSTABILITY; DNA DAMAGE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR VIRUS;

ADOLESCENT; ADULT; AGED; ALTERNATIVE SPLICING; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTEIN KINASES; PROTEIN PHOSPHATASE 2;

EID: 35348930441     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9461-z     Document Type: Article

References (47)

1. Ford D, Easton DF et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676-689
2. Smith P, McGuffog L et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45:646-655
3. Antoniou AC, Pharoah PD et al (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1-18
4. Zhang J, Powell SN (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 3:531-539
5. The CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*11100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-82
6. Khanna KK, Chenevix-Trench G (2004) ATM and genome maintenance: defining its role in breast cancer susceptibility. J Mammary Gland Biol Neoplasia 9:247-262
7. Cimprich KA, Shin TB et al (1996) cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl Acad Sci USA 93:2850-2855
8. Sancar A, Lindsey-Boltz LA et al (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39-85
9. Brown LT, Sexsmith E et al (2000) Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet 123:65-68
10. de Klein A, Muijtjens M et al (2000) Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 10:479-482
11. Davies H, Hunter C et al (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591-7595
12. Stephens P, Edkins S et al (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37:590-592
13. Lash AE, Tolstoshev CM et al (2000) SAGEmap: a public gene expression resource. Genome Res 10:1051-1060
14. Strausberg RL, Buetow KH et al (2000) The cancer genome anatomy project: building an annotated gene index. Trends Genet 16:103-106
15. Alderton GK, Joenje H et al (2004) Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum Mol Genet 13:3127-3138
16. O'Driscoll M, Ruiz-Perez VL et al (2003) A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33:497-501
17. Liu Q, Guntuku S et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459
18. Gatei M, Sloper K et al (2003) Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278:14806-14811
19. Yarden RI, Pardo-Reoyo S et al (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285-289
20. Lam MH, Liu Q et al (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6:45-59
21. Gentile M, Ahnstrom M et al (2001) Candidate tumour suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene 20:7753-7760
22. Bougeret C, Jiang S et al (2001) Functional analysis of Csk and CHK kinases in breast cancer cells. J Biol Chem 276:33711-33720
23. Goodarzi AA, Jonnalagadda JC et al (2004) Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. Embo J 23:4451-4461
24. Wang SS, Esplin ED et al (1998) Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282:284-287
25. Ruediger R, Pham HT et al (2001) Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20:10-15
26. Esplin ED, Ramos P et al (2006) The glycine 90 to aspartate alteration in the A beta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer 45:182-190
27. Rasmussen SB, Kordon E et al (2001) Evidence for the transforming activity of a truncated Int6 gene, in vitro. Oncogene 20:5291-5301
28. Asano K, Merrick WC et al (1997) The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome. J Biol Chem 272:23477-23480
29. Miyazaki S, Imatani A et al (1997) The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. Genomics 46:155-158
30. Morris C, Jalinot P (2005) Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation. Oncogene 24:1203-1211
31. Mann GJ, Thorne H et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12-R26
32. Lewis AG, Flanagan J et al (2005) Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 7:R1005-R1016
33. Chenevix-Trench G, Spurdle AB et al (2002) Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94:205-215
34. Miller SA, Dykes DD et al (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
35. Frueh FW, Noyer-Weidner M (2003) The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 41:452-461
36. Jones AC, Austin J et al (1999) Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 45:1133-1140
37. Spiegelman JI, Mindrinos MN et al (2000) High-accuracy DNA sequence variation screening by DHPLC. Biotechniques 29(1084-1090):1092
38. Thompson D, Easton DF et al (2003) A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73:652-655
39. Levi S, Urbano Ispizua A et al (1991) Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51:3497-3502
40. Claus EB, Risch NJ et al (1990) Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131:961-972
41. Heikkinen K, Mansikka V et al (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 7:R495-R501
42. Durocher F, Labrie Y et al (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230
43. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
44. Chabanon H, Mickleburgh I et al (2004) Zipcodes and postage stamps: mRNA localisation signals and their trans-acting binding proteins. Brief Funct Genom Proteom 3:240-256
45. Mann GJ, Thorne H et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12
46. Thompson D, Antoniou AC et al (2005) Two ATM variants and breast cancer risk. Hum Mutat 25:594-595
47. Bernstein JL, Teraoka S et al (2006) Population-based estimates of breast cancer risks associated with ATM gene variants c.7271 T > G and c.1066-6 T > G (IVS10-6 T > G) from the Breast Cancer Family Registry. Hum Mutat 27(11):1122-1128